Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Quoin ...

Quoin Pharmaceuticals (QNRX) announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares represented by 15,111,110 American Depositary Shares, Series F ...

Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing ...

(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Wednesday, announced positive interim data from two ongoing clinical trials for topical lotion ...

Quoin Pharmaceuticals, Inc. ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical ...

ASHBURN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty ...